DNA origami vaccines program antigen-focused germinal centers
Authors:
- Anna RomanovARAnna Romanov
- Grant A. KnappeGKGrant A. Knappe
- Larance RonsardLRLarance Ronsard
- Christopher A. CottrellCCChristopher A. Cottrell
- Yiming J. ZhangYZYiming J. Zhang
- Asheley P. ChapmanACAsheley P. Chapman
- Katie SpivakovskyKSKatie Spivakovsky
- Patrick SkogPSPatrick Skog
- Claudia T. FlynnCFClaudia T. Flynn
Top Cited Papers
- 5 February 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6785) , eadx6291
Abstract
Priming rare subdominant precursor B cells in germinal centers (GCs) is a central goal of vaccination to generate broadly neutralizing antibodies (bnAbs) against HIV. Multivalent immunogen display on protein nanoparticle scaffolds can promote such responses, but it also generates scaffold-specific B cells that could theoretically limit bnAb precursor expansion in GCs. We rationally designed DNA origami–based virus-like particles (DNA-VLPs) displaying a germline-targeting HIV envelope protein immunogen, which elicited no scaffold-specific antibody responses. Compared with a state-of-the-art clinical protein nanoparticle, these DNA-VLPs increased the expansion of epitope-specific GC B cells relative to off-target B cells and enhanced expansion of bnAb-lineage B cells in a humanized mouse model of CD4 binding site priming. Thus, minimizing off-target responses enhances bnAb priming and indicates that DNA-VLPs are a promising vaccine platform.Keywords
All Related Versions
Funding Information
- National Institutes of Health (P30-ES002109)
- National Institutes of Health (R01-AI162307-03)
- National Institutes of Health (R01-AI153098)
- National Institutes of Health (AI144462)
- Howard Hughes Medical Institute
- National Cancer Institute (P30-CA14051)
- Bill and Melinda Gates Foundation (NAC INV-007522)
- Bill and Melinda Gates Foundation (INV-008813)
- Bill and Melinda Gates Foundation (INV-034657)
- National Science Foundation Fellowship (4000168384)
- Novo Nordisk Fonden (NNF23OC0082848)
- National Science Foundation Fellowship (4000189657)
This publication has 98 references indexed in Scilit:
- A percolation phase transition controls complement protein coating of surfacesCell, 2025
- Cargo Quantification of Functionalized DNA Origami for Therapeutic ApplicationSmall Methods, 2024
- Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trialeClinicalMedicine, 2022
- DNA Origami Nanostructures Elicit Dose‐Dependent Immunogenicity and Are Nontoxic up to High Doses In VivoSmall, 2022
- Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogensCell Reports, 2022
- Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial VirusCell, 2019
- Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine ImmunogensImmunity, 2018
- The Pathway to a Universal Influenza VaccineImmunity, 2017
- Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor RepertoiresCell, 2016
- The mammalian gene function resource: the international knockout mouse consortiumMammalian Genome, 2012